BioCryst Pharmaceuticals, Inc. (BCRX) Earnings History
Annual and quarterly earnings data from 1994 to 2025
Loading earnings history...
BCRX EPS Growth (CAGR)
Compound annual growth rate of diluted earnings per share
CAGR (Compound Annual Growth Rate) shows the annualized growth rate of EPS over the specified period. A higher CAGR indicates stronger earnings momentum.
BCRX Profitability Analysis
Margin trends over time
| Year | Gross Margin | Operating Margin | Net Margin |
|---|---|---|---|
| 2025 | 97.8% | 39.0% | 30.2% |
| 2024 | 97.2% | -0.6% | -19.7% |
| 2023 | 98.6% | -31.3% | -68.4% |
| 2022 | 97.6% | -54.8% | -91.2% |
| 2021 | 95.4% | -113.1% | -117.1% |
Download Data
Export BCRX earnings history in CSV or JSON format
Free sign-in required to download data
BioCryst Pharmaceuticals, Inc. (BCRX) Earnings Overview
As of May 8, 2026, BioCryst Pharmaceuticals, Inc. (BCRX) reported trailing twelve-month net income of -$458M, reflecting +381.4% year-over-year growth. The company earned $-1.89 per diluted share over the past four quarters, with a net profit margin of 30.2%.
Looking at the long-term picture, BCRX's historical earnings data spans multiple years. The company achieved its highest annual net income of $264M in fiscal 2025, representing a new all-time high.
BioCryst Pharmaceuticals, Inc. is currently reporting a net loss, though operating performance should be evaluated in the context of growth investments and industry dynamics View revenue history →
Compared to peers including RARE (-$609M net income, -85.4% margin), FOLD (-$27M net income, -4.3% margin), ACAD ($376M net income, 36.5% margin), BCRX has outperformed on profitability metrics. Compare BCRX vs RARE →
BCRX Earnings vs Peers
Earnings metrics vs comparable public companies
BCRX Historical Earnings Data (1994–2025)
32 years| Fiscal Year | Net Income | YoY % | Operating Income | EPS (Diluted) | Net Margin | Op. Margin |
|---|---|---|---|---|---|---|
| 2025 | $264M | +396.9% | $341M | $1.21 | 30.2% | 39.0% |
| 2024 | -$89M | +60.8% | -$3M | $-0.43 | -19.7% | -0.6% |
| 2023 | -$227M | +8.3% | -$104M | $-1.18 | -68.4% | -31.3% |
| 2022 | -$247M | -34.3% | -$148M | $-1.33 | -91.2% | -54.8% |
| 2021 | -$184M | -0.7% | -$178M | $-1.03 | -117.1% | -113.1% |
| 2020 | -$183M | -67.9% | -$175M | $-1.09 | -1026.4% | -981.1% |
| 2019 | -$109M | -7.6% | -$99M | $-0.94 | -223.0% | -203.7% |
| 2018 | -$101M | -53.9% | -$94M | $-0.98 | -490.3% | -456.2% |
| 2017 | -$66M | -19.3% | -$57M | $-0.78 | -261.2% | -227.9% |
| 2016 | -$55M | -28.2% | -$49M | $-0.75 | -209.3% | -184.4% |
See BCRX's True Return
Price is only half the story. See total return with reinvested dividends.
Launch CalculatorIs BCRX Undervalued?
DCF intrinsic value, peer multiples, and analyst estimates — see what the stock is really worth.
View ValuationCompare BCRX vs DBVT
Side-by-side business, growth, and profitability comparison vs DBV Technologies S.A..
Start ComparisonBCRX — Frequently Asked Questions
Quick answers to the most common questions about buying BCRX stock.
Is BCRX growing earnings?
BCRX EPS is $-1.89, with earnings growth accelerating to +381.4%. This exceeds the 5-year CAGR of N/A. TTM net income reached $-458M.
What are BCRX's profit margins?
BioCryst Pharmaceuticals, Inc. net margin is +30.2%, with operating margin at +39.0%. Above-average margins indicate pricing power.
How consistent are BCRX's earnings?
BCRX earnings data spans 1994-2025. The accelerating earnings trend is +381.4% YoY. Historical data enables comparison across business cycles.